Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Status:
Not yet recruiting
Trial end date:
2024-06-10
Target enrollment:
Participant gender:
Summary
This is a Phase 2, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults with Nonalcoholic Steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Gannex Pharma Co., Ltd.